Research programme: serotonin receptor-targeted therapeutics - Neurolixis

Drug Profile

Research programme: serotonin receptor-targeted therapeutics - Neurolixis

Alternative Names: Befiradol - Neurolixis; F-13640 - Neurolixis; F-15599 - Neurolixis

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis
  • Class Non-opioid analgesics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rett syndrome
  • No development reported Drug-induced dyskinesia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA
  • 06 Mar 2014 Research programme: serotonin receptor-targeted therapeutics - Neurolixis receives Orphan Drug status for Rett syndrome in European Union
  • 05 Nov 2013 Research programme: serotonin receptor-targeted therapeutics - Neurolixis receives Orphan Drug status for Rett syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top